NEWS – Nigeria has become the first country in the world to roll out a new vaccine (Men5CV) recommended by the World Health Organization (WHO) to protect against five strains of the meningococcus bacteria

Men5CV

• Men5CV vaccine targets five major meningococcal bacteria strains in a single shot, offering broader protection.
• Developed through a 13-year partnership between PATH and the Serum Institute of India + for development came from the UK government’s Foreign, Commonwealth and Development Office.
• Utilizes the same technology as MenAfriVac®, which successfully eliminated meningococcal A epidemics in Nigeria.
• Men5CV vaccine received WHO prequalification in July 2023, with an official recommendation for global adoption in October 2023
• Branded as MenFive®, officially recommended by WHO, and received funding from the UK government, with support from GAVI for rollout in high-risk areas like Nigeria

MENINGITIS

• Definition: Meningitis is inflammation of the membranes covering the brain and spinal cord.
• Causes: It can be caused by bacteria, viruses, certain medicines, or illnesses.
• Transmission: Typically spreads through contact like touching, kissing, or coughing/sneezing on others.
• Types: Viral meningitis is more common and less severe, while bacterial meningitis is rare but serious.
• Symptoms: Include fever, headache, stiff neck, sensitivity to light, and skin rash.
• Treatment: Vaccines like meningococcal, Haemophilus influenzae type b, and pneumococcal vaccines offer protection. Early treatment is vital for successful recovery